Global Schizophrenia Drugs Market 2021-2025

Global Schizophrenia Drugs Market 2021-2025

Technavio has been monitoring the schizophrenia drugs market and it is poised to grow by $ 957.50 mn during 2021-2025, progressing at a CAGR of 2.06% during the forecast period. Our report on the schizophrenia drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing expenditure on prescription drugs and increasing awareness programs. In addition, increasing expenditure on prescription drugs is anticipated to boost the growth of the market as well.

The schizophrenia drugs market analysis includes the drug class segment and geographic landscape.

Technavio's schizophrenia drugs market is segmented as below:

By Drug Class

• Second-generation antipsychotic drugs
• Third-generation antipsychotic drugs
• First-generation antipsychotic drugs

By Geographical Landscape

• North America
• Europe
• Asia
• ROW

This study identifies the enhanced next-generation productsas one of the prime reasons driving the schizophrenia drugs market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on schizophrenia drugs market covers the following areas:

• Schizophrenia drugs market sizing
• Schizophrenia drugs market forecast
• Schizophrenia drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading schizophrenia drugs market vendors that include AbbVie Inc., Alkem Laboratories Ltd., Alkermes Plc, AstraZeneca Plc, Biogen Inc., Boehringer Ingelheim International GmbH, Dr. Reddys Laboratories Ltd., Eli Lilly and Co., Johnson and Johnson Inc., and Otsuka Holdings Co. Ltd. Also, the schizophrenia drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Companies Mentioned

AbbVie Inc., Alkem Laboratories Ltd., Alkermes Plc, AstraZeneca Plc, Biogen Inc., Boehringer Ingelheim International GmbH, Dr. Reddys Laboratories Ltd., Eli Lilly and Co., Johnson and Johnson Inc., Otsuka Holdings Co. Ltd.